Optimise viewing for

Toggle between patient and health professional views. The patient version is simplified to help people easily find suitable trials, while the professional view provides full detail.

RecruitingLast updated: 1 October 2026

I-FIRST: Targeted therapy to enhance treatment for people with thyroid cancer with NRAS or BRAFV600E mutations who no longer respond to standard treatment with radioactive iodineA Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer

Trial purpose

Medical clipboardCancer treatment

Tumor type

Thyroid Cancer Thyroid

Age

People18+

Trial acronym

I-FIRST

Clinical summary

Summary

This clinical trial is testing whether targeted cancer medicines can help thyroid cancers become sensitive to radioactive iodine treatment again.

Some people with differentiated thyroid cancer stop responding to radioactive iodine, which is a common treatment for thyroid cancer. Researchers believe that certain targeted therapies may help these cancers take up radioactive iodine again, making the treatment effective once more.

Who can take part?
You may be eligible for this study if:

  • you are aged 18 years or older
  • you have differentiated thyroid cancer
  • your cancer no longer responds to radioactive iodine treatment
  • your cancer has a change (mutation) in either the BRAF V600E or NRAS gene
  • your cancer can be measured using standard imaging scans

Study details
Participants will receive either:

  • Trametinib tablets, if their cancer has a NRAS mutation, or
  • Trametinib and dabrafenib tablets, if their cancer has a BRAF V600E mutation

These medicines will be taken for about 30 days.

Before starting treatment, participants will:

  • Follow a low-iodine diet
  • Temporarily stop their usual thyroid hormone medication and switch to an alternative thyroid hormone to help reduce symptoms
  • Have specialised PET/CT scans and radioactive iodine imaging to assess how well their cancer absorbs iodine

After approximately 3 weeks of treatment, participants will have repeat scans to see whether the targeted therapy has improved iodine uptake in their cancer.

If the scans show that the cancer is absorbing enough radioactive iodine, participants will receive a standard treatment dose of radioactive iodine (iodine-131).

After treatment, participants will be monitored with regular scans, blood tests and quality of life questionnaires. Follow-up will continue for several years to assess how well the treatment works and to track long-term outcomes.

Conditions

This trial is treating people with radioiodine refractory differentiated thyroid cancer

Eligibility

Inclusion

  1. Histologically-confirmed differentiated (including poorly differentiated) thyroid cancer that is either locally advanced or metastatic.
  2. Age > 18 years.
  3. Life expectancy > 12 weeks.
  4. Documented radiological progression by RECIST 1.1 in last 12 months.
  5. Radioiodine refractory (at least one of):

    1. one measurable lesion without radioiodine uptake on 131I scan,
    2. at least one measurable lesion that had progressed by RECIST criteria within 12 months of 131I therapy despite 131I avidity at time of treatment, or
    3. cumulative treatment with >24 GBq (600 mCi) of 131I.
  6. At least one evaluable lesion as per RECIST v1.1 that has not been treated with local radiation therapy within 3 months prior to the first dose of TKI. Irradiated lesions can only be included as an evaluable lesion if it has shown radiological progression as per RECIST v1.1 on subsequent imaging following irradiation.
  7. NRAS or BRAF V600E mutation tested by NGS in a NATA accredited laboratory or by recognised sequencing platform.
  8. ECOG 0-1.
  9. Informed consent.
  10. Adequate haematological and biochemical parameters:

    1. Haemoglobin ≥ 9g/dL
    2. Neutrophils ≥ 1.5 x 109/L
    3. Platelets ≥ 100 x 109/L
    4. INR ≤ 1.4
    5. Serum Creatinine ≤ 1.3 x ULN
    6. Estimated Creatinine Clearance ≥ 30 ml/min (by Cockcroft Gault Formula)
    7. Serum ALT and AST ≤ 2.5 x ULN
    8. Serum Total Bilirubin ≤ 1.5 x ULN.
    9. TSH suppression <0.1mU/L or otherwise consistent with 2015 ATA Guidelines on Thyroid Cancer

Exclusion

  1. Anaplastic thyroid cancer.
  2. Suitable for curative surgery or radiotherapy.
  3. Other anti-cancer (including TKI) therapy in prior 6 weeks.
  4. Concurrent malignancy other than non-melanoma skin cancer. Prior malignancies treated with curative intent and no evidence of recurrence in past three years may be allowed upon discussion with the medical monitor.
  5. Unstable brain metastasis. Treated or non-treated brain metastasis are allowed if neurologically stable, asymptomatic, on a stable steroid dose for a period of 2 weeks, and not anticipated to require any intervention during the trial treatment period. If treated with radiation or surgery, any related AE's should have recovered to ≤ grade 1 prior to enrolment on trial.
  6. Pregnancy, breastfeeding or unwilling to use contraception in those of child-bearing age.
  7. Significant medical condition that would prevent compliance with study procedures.
  8. History of retinal vein occlusion or retinopathy.
  9. Iodine-containing contrast scan within 8 weeks of planned 124I scan.

Inclusion

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You are able to swallow medication by mouth.
  • You have the type of cancer, symptoms, or health risks that this clinical trial is focused on.

Exclusion

  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.
Message

Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.

Participating hospitals

Recruiting hospitals

+ Show non-recruiting hospitals

No longer recruiting (closed or complete) hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

More information

Trial Identifiers

Information on this page is partially produced from ClinicalTrials.gov *. View further details about this trial on the registry via the links below:

Trial sponsor

Olivia Newton-John Cancer Research Institute

Scientific Title

A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer

Trial added to VCTL (data sourced from registry): June 2022
Trial information last reviewed by VCTL: September 2026

Get Support

Peer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Know more about Peer Connect

Contact cancer support

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.

Get support

Multilingual information

Learn more about clinical trials through this collection of resources in languages other than English.

View information